Skip to main content

Prelude Therapeutics Inc (NASDAQ: PRLD) — Company Overview, News & Financial Data

Prelude Therapeutics Inc logo
PRLD Prelude Therapeutics Inc
Prelude Therapeutics Inc primary media
Company profile

Prelude Therapeutics Inc

Prelude Therapeutics (NASDAQ:PRLD) is a biotechnology company dedicated to advancing innovative treatments in oncology and rare diseases. With a keen focus on drug discovery and development, Prelude is working diligently to bring novel cancer therapies from the laboratory to clinical trials, aiming to address unmet medical needs. Their pipeline includes a range of small-molecule therapeutics designed to target key signaling pathways in cancer cells, showcasing their commitment to transforming the landscape of cancer treatment. Central to the company's objectives is the pursuit of scientific breakthroughs that can lead to life-changing treatments for patients battling cancer and other serious diseases.

Snapshot

Public USOwnership
2016Year founded
128Employees
Wilmington, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Wilmington, US

Products and/or services of Prelude Therapeutics Inc

  • PRT543, a small molecule inhibitor targeting PRMT5, designed for treating a variety of cancers including solid tumors and hematological malignancies.
  • PRT811, a PRMT5 inhibitor with potential broad application in solid tumors, particularly glioblastoma.
  • PRT2527, a CDK9 inhibitor aiming at treating MYC-driven cancers, including hematologic malignancies and solid tumors.
  • PRT1419, an MCL1 inhibitor intended for patients with hematologic malignancies, addressing a key survival protein in cancer cells.
  • PRT3645, a potent inhibitor focusing on PI3K delta, developed for treating hematologic malignancies.

Prelude Therapeutics Inc executive team

  • Krishna VaddiFounder, CEO & Director
  • Bryant David LimCFO, Chief Legal Officer & Corporate Secretary
  • Peggy A. ScherleChief Scientific Officer
  • Aimee CrombieSenior VP and Head of Strategic Planning & Operations
  • Madhu PudipeddiSenior Vice President of Technical Operations
  • Robert A. Doody Jr.Senior Vice President of Investor Relations
  • Michele PorrecaChief People Officer
  • Andrew P. CombsExecutive VP & Chief Chemistry Officer
  • Naveen BabbarSenior Vice President of Translation Medicine
  • Wan-Jen HongSenior Vice President of Clinical Development

Recent announcements

What Prelude Therapeutics Inc (PRLD) has told the market, newest first.

Key financials

Reported results for Prelude Therapeutics Inc, in USD.

Market cap
280.9M
Revenue (TTM)
22.4M
P/E ratio
—
EPS (diluted, TTM)
-0.7
Dividend yield
—
Profit margin
-269.8%
Prelude Therapeutics Inc annual revenue and income
Fiscal year endRevenueOperating incomeNet income
12.1M-104.6M-99.5M
7M-139.7M-127.2M
0-132.3M-121.8M
0-123.5M-107.3M